The supply agreement follows the development and scale-up of a new affinity resin, which is intended to develop the quality and purity of an existing biopharmaceutical product.
The partnership signifies the beginning of the commercial supply of the new affinity resin for use in the manufacturing of the biopharmaceutical product.
The new resin is expected to generate total revenues of over $6.0m annually.
ProMetic BioSciences CEO Dr Steve Burton said, "The superior product quality and purity profile derived from the utilization of ProMetic’s affinity technology places our client in a position to increase its respective market share."